- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07366034
Et studie til at undersøge, hvordan Nerandomilast tolereres, håndteres af kroppen, og om det hjælper børn og unge med interstitiel lungesygdom
En undersøgelse til evaluering af dosis-eksponering, sikkerhed og eksplorativ effekt af Nerandomilast hos børn og unge fra 2 år til under 18 år med fibroserende interstitiel lungesygdom (Del A: Dobbeltblind, placebo-kontrolleret hos børn fra 6 til under 18 år og åben-label aktiv behandling hos børn fra 2 til under 6 år), efterfulgt af en åben-label fase med aktiv behandling (Del B)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary fibrosis. The purpose of this study is to understand how nerandomilast is tolerated and handled by the body and whether nerandomilast also helps children and adolescents with ILD.
For participants aged 6 to 17 years when joining, the study has 2 parts. In the first part, participants are put into 1 of 2 groups randomly, which means by chance. One group gets nerandomilast and the other group placebo. Placebo looks like nerandomilast but does not contain any medicine.
Participants are twice as likely to be in the nerandomilast group. They take tablets twice a day for 6 months. After these 6 months, in the second part of this study, they get nerandomilast for at least 2 years regardless of what they got in the first part.
Young participants aged 2 to 5 years when joining get nerandomilast from the start. They receive tablets twice a day for at least 2 and a half years.
Depending on when a person joins, the study lasts between 2 and a half years and up to 5 years. During this time, participants may visit the study site about 18 to 30 times. Study doctors collect blood samples to check participants' health and to find out how their body handles the study medicine. Doctors also check the function of the lungs, body growth, and how participants feel. The study doctors also regularly check participants' health and take note of any changes. For participants aged 6 to 17 years, the results are compared between the groups to see whether nerandomilast treatment helps children and adolescents.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Boehringer Ingelheim
- Telefonnummer: 1-800-243-0127
- E-mail: clintriage.rdg@boehringer-ingelheim.com
Studiesteder
-
-
-
CABA, Argentina, 1426
- Rekruttering
- Fundacion Respirar
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08002667801
- E-mail: argentina@bitrialsupport.com
-
-
-
-
South Australia
-
North Adelaide, South Australia, Australien, 5006
- Rekruttering
- Women's and Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 1800271035
- E-mail: australia@bitrialsupport.com
-
-
-
-
-
Brussels, Belgien, 1020
- Rekruttering
- Brussels - UNIV HUDERF
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 080049616
- E-mail: belgique@bitrialsupport.com
-
-
-
-
-
Barra Mansa, Brasilien, 27323240
- Rekruttering
- Serviços Medicos Respirar Sul Fluminense
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08008919295
- E-mail: brasil@bitrialsupport.com
-
Porto Alegre, Brasilien, 90160-093
- Rekruttering
- Associação dos Funcionários Públicos do Estado do Rio Grande do Sul - Hospital Ernesto Dorneles
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08008919295
- E-mail: brasil@bitrialsupport.com
-
Recife, Brasilien, 50070-550
- Rekruttering
- IMIP Pernambuco
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08008919295
- E-mail: brasil@bitrialsupport.com
-
São Paulo, Brasilien, 5403-900
- Rekruttering
- Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08008919295
- E-mail: brasil@bitrialsupport.com
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Ikke rekrutterer endnu
- Alberta Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-mail: canada@bitrialsupport.com
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Ikke rekrutterer endnu
- The Hospital for Sick Children
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-mail: canada@bitrialsupport.com
-
-
-
-
-
Aarhus N, Danmark, 8200
- Ikke rekrutterer endnu
- Aarhus University Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 80711822
- E-mail: danmark@bitrialsupport.com
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B4 6NH
- Ikke rekrutterer endnu
- Birmingham Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08000514022
- E-mail: unitedkingdom@bitrialsupport.com
-
London, Det Forenede Kongerige, SE5 9RS
- Rekruttering
- King's College Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08000514022
- E-mail: unitedkingdom@bitrialsupport.com
-
-
-
-
-
Helsinki, Finland, PL 281, 00029
- Ikke rekrutterer endnu
- HUS Lasten ja nuorten sairaudet, Kliinisen tutkimuksen yksikkö
-
Tampere, Finland, 33520
- Rekruttering
- Tampere University Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0800918118
- E-mail: suomi@bitrialsupport.com
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Ikke rekrutterer endnu
- Children's Hospital Los Angeles
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Children's Hospital Colorado
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Ikke rekrutterer endnu
- Johns Hopkins Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Boston Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55454
- Rekruttering
- M Health Fairview Masonic Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43205
- Ikke rekrutterer endnu
- Nationwide Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Ikke rekrutterer endnu
- Children's Hospital of Philadelphia
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
-
-
-
Bron, Frankrig, 69677
- Rekruttering
- HOP Femme Mère Enfant
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0805102354
- E-mail: france@bitrialsupport.com
-
Créteil, Frankrig, 94000
- Rekruttering
- HOP Intercommunal
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0805102354
- E-mail: france@bitrialsupport.com
-
Marseille, Frankrig, 13387
- Ikke rekrutterer endnu
- HOP Timone
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0805102354
- E-mail: france@bitrialsupport.com
-
Paris, Frankrig, 75012
- Ikke rekrutterer endnu
- HOP Armand-Trousseau
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0805102354
- E-mail: france@bitrialsupport.com
-
Paris, Frankrig, 75015
- Rekruttering
- HOP Necker - Enfants Malades
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0805102354
- E-mail: france@bitrialsupport.com
-
-
-
-
-
Thessaloniki, Grækenland, 54642
- Ikke rekrutterer endnu
- Aristotle University, Thessaloniki
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 008000000092
- E-mail: hellas@bitrialsupport.com
-
-
-
-
-
Amsterdam, Holland, 1105 AZ
- Ikke rekrutterer endnu
- Amsterdam University Medical Center
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08000204613
- E-mail: nederland@bitrialsupport.com
-
-
-
-
-
Genova, Italien, 16147
- Rekruttering
- Istituto G. Gaslini
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 800977373
- E-mail: italia@bitrialsupport.com
-
Roma, Italien, 00165
- Ikke rekrutterer endnu
- Ospedale Pediatrico Bambino Gesù
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 800977373
- E-mail: italia@bitrialsupport.com
-
-
-
-
-
Fukuoka, Fukuoka, Japan, 813-0017
- Ikke rekrutterer endnu
- Fukuoka Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Osaka, Izumi, Japan, 594-1101
- Ikke rekrutterer endnu
- Osaka Women's and Children's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Tokyo, Setagaya-ku, Japan, 157-8535
- Rekruttering
- National Center for Child Health and Development
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 05050508862
- E-mail: nippon@bitrialsupport.com
-
-
-
-
-
Beijing, Kina, 100045
- Rekruttering
- Beijing Children's Hospital, Capital Medical University
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 4001200553
- E-mail: china@bitrialsupport.com
-
Changsha, Kina, 410005
- Rekruttering
- Hunan Provincial People's Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 4001200553
- E-mail: china@bitrialsupport.com
-
Shanghai, Kina, 201102
- Rekruttering
- The Children's Hospital of Fudan University
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 4001200553
- E-mail: china@bitrialsupport.com
-
-
-
-
-
Guadalajara, Mexico, 44340
- Ikke rekrutterer endnu
- Centro de Investigacion Clinica y Medicina Traslacional (CIMeT)
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 018000623749
- E-mail: mexico@bitrialsupport.com
-
Tlalnepantla, Mexico, 54055
- Ikke rekrutterer endnu
- Clinical Research Institute S.C.
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 018000623749
- E-mail: mexico@bitrialsupport.com
-
-
-
-
-
Warsaw, Polen, 02 091
- Ikke rekrutterer endnu
- University Clinical Center of the Medical University of Warsaw
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 008001218830
- E-mail: polska@bitrialsupport.com
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Ikke rekrutterer endnu
- ULS de Santa Maria, E.P.E - Hospital de Santa Maria
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 800856070
- E-mail: portugal@bitrialsupport.com
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 900876092
- E-mail: espana@bitrialsupport.com
-
Seville, Spanien, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 900876092
- E-mail: espana@bitrialsupport.com
-
-
-
-
-
Seoul, Sydkorea, 03080
- Rekruttering
- Seoul National University Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0808802084
- E-mail: namhan@bitrialsupport.com
-
-
-
-
-
Prague, Tjekkiet, 150 00
- Ikke rekrutterer endnu
- University Hospital Motol
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 800142046
- E-mail: cesko@bitrialsupport.com
-
-
-
-
-
Berlin, Tyskland, 13353
- Rekruttering
- Charité - Universitätsmedizin Berlin
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
Hamburg, Tyskland, 22081
- Rekruttering
- Hamburger Zentrum für Kinder- und Jugendrheumatologie
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
Hanover, Tyskland, 30625
- Rekruttering
- Medizinische Hochschule Hannover
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Children and adolescents 2 to <18 years old at Visit 2.
-
Participants with evidence of fibrosing ILD on high-resolution computed tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
-
For children ≥6 years: Participants with forced vital capacity (FVC) % predicted ≥25% at Visit 2.
-
Participants with clinically significant fibrosing ILD at Visit 2, as assessed by the investigator based on any of the following:
-
Fan score ≥3, or
-
Documented evidence of clinical progression over time based on either
- a 5-10% relative decline in FVC % predicted accompanied by worsening symptoms, or
- a ≥10% relative decline in FVC % predicted, or
- increased fibrosis on HRCT, or
- other measures of clinical worsening attributed to progressive lung disease (e.g. increased oxygen requirement, decreased diffusion capacity).
-
Further inclusion criteria apply.
Exclusion Criteria:
- Previous treatment with nerandomilast.
- Participants treated with other oral/systemic PDE4 and non-selective PDE inhibitors within 30 days before Visit 1.
- Participants treated with pirfenidone in the 8 weeks prior to Visit 1.
- Unstable pulmonary arterial hypertension (PAH).
- Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period.
- Any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour) in the past (lifetime).
- Any suicidal ideation of type 4 or 5 on the columbia suicidal severity rating scale (C-SSRS) in the past 3 months at Visit 1 or at Visit 2 (i.e. active suicidal thought with method and intent but without specific plan; or active suicidal thought with method, intent, and plan).
- Participants with clinically significant depression symptoms defined as the short version of mood and feeling questionnaire (SMFQ) score ≥8.
Further exclusion criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Participants aged 2 to <6 years
Part A and Part B: Nerandomilast (open-label) |
Nerandomilast
Andre navne:
|
|
Eksperimentel: Participants aged 6 to <18 years, group 1
Part A: Nerandomilast (blinded), Part B: Nerandomilast (open-label) |
Nerandomilast
Andre navne:
|
|
Eksperimentel: Participants aged 6 to <18 years, group 2
Part A: Placebo (blinded), Part B: Nerandomilast (open-label) |
Placebo |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Areal under koncentrationskurven (AUC) T,SS baseret på prøvetagning i steady state ved brug af rig prøvetagning hos deltagere fra 6 år til under 18 år og sparsom prøvetagning hos deltagere under 6 år
Tidsramme: I uge 2 i del A og uge 28 i del B
|
I uge 2 i del A og uge 28 i del B
|
|
Forekomst af en behandlingsrelateret bivirkning
Tidsramme: op til uge 26
|
op til uge 26
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Absolut ændring fra baseline i iltmætning (SpO2) [%] på stuetempereret luft i hvile
Tidsramme: ved uge 26 og uge 52
|
ved uge 26 og uge 52
|
|
|
Absolut ændring fra baseline i højde [cm]
Tidsramme: ved uge 26 og uge 52
|
ved uge 26 og uge 52
|
|
|
Forekomst af en behandlingsrelateret bivirkning (Ja/Nej) i hele forsøgets varighed
Tidsramme: op til 5 år
|
op til 5 år
|
|
|
Tid til første respiratorisk relateret indlæggelse [dage] over hele forsøget
Tidsramme: op til 5 år
|
op til 5 år
|
|
|
Tid til første akut interstitiel lungesygdom (ILD) eksacerbation eller død [dage] gennem hele forsøget
Tidsramme: op til 5 år
|
op til 5 år
|
|
|
Tid til død [dage] i hele forsøget
Tidsramme: op til 5 år
|
op til 5 år
|
|
|
Absolut ændring fra baseline i FVC [% forventet] (gælder for deltagere ≥6 år)
Tidsramme: ved uge 26 og uge 52
|
ved uge 26 og uge 52
|
|
|
Absolut ændring fra baseline i 6-minutters gangdistance [m] (gælder for deltagere ≥6 år)
Tidsramme: ved uge 26 og uge 52
|
ved uge 26 og uge 52
|
|
|
Acceptabilitet baseret på brug af dispenseren
Tidsramme: i uge 2 og uge 26
|
i uge 2 og uge 26
|
|
|
Absolute change from baseline in pediatric quality of life inventory (PedsQL™)
Tidsramme: at Week 26 and Week 52
|
Health-related quality of life will be assessed in children using the PedsQL™ questionnaire. For younger children who are unable to perform self-assessment, a parent proxy may be required. The score ranges from 0-100, a higher score indicates a better health related quality of life. |
at Week 26 and Week 52
|
|
Acceptability based on number/size of tablets
Tidsramme: at Week 2 and Week 26
|
Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Assessment of acceptability will be performed by the participant using the acceptability questionnaire. |
at Week 2 and Week 26
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 1305-0022
- 2025-523369-32-00 (Registry Identifier: CTIS (EU))
- 1111-1326-6351 (Registry Identifier: WHO - International Clinical Trials Registry Platform (ICTRP))
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-delingstidsramme
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD-delingsadgangskriterier
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .